News
-
-
-
PRESS RELEASE
Original-Research: Rakovina Therapeutics Inc. (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Rakovina Therapeutics Inc. with a Buy recommendation and CAD 0.40 target price. Rakovina focuses on DNA Damage Response pathways in developing next-gen cancer treatments